Amphastar Pharmaceuticals, Inc. (AMPH) Q4 FY25 Earnings Call

2026 growth is expected to accelerate, but pricing pressure and higher costs should reduce gross margins.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-01
Length27 minutes
EPS$0.61
EPS consensus$0.89
Revenue$191.8M
Revenue consensus$189.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All AMPH earnings ยท Back to AMPH overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.